Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development

• Published in: Bone (New York, N.Y.) Vol. 167; p. 116637
• Main Authors: Chirokikh, Alexander A., Uddin, Sardar M.Z., Areikat, Nadine, Jones, Rachel, Duque, Edie, Connor, Carly, Hadjiargyrou, Michael, Thanos, Panayotis K., Komatsu, David E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2023
• Subjects: Animals; Body Weight; Fluoxetine; Fluoxetine - pharmacology; Fluoxetine - therapeutic use; Male; Methylphenidate; Methylphenidate - pharmacology; Rat; Rats; Rats, Sprague-Dawley; Skeletal development; Weight Gain; fluoxetine; Rat; mixed salts amphetamine; Selective-serotonin reuptake inhibitors; Attention-Deficit/Hyperactivity Disorder; Skeletal development; hematopoietic stem cells; Methylphenidate; Fluoxetine
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2022.116637

Methylphenidate (MP) is frequently prescribed to treat Attention-Deficit/Hyperactivity Disorder (ADHD); however, many patients with ADHD experience depression and anxiety. As such, concomitant administration of selective serotonin reuptake inhibitors such as fluoxetine (FLX) is common. Our laboratory and others have shown that MP impairs skeletal development in preclinical and clinical settings, and FLX has also been linked to skeletal deficits. Unfortunately, little is known about the effects of combined MP and FLX treatment on skeletal development. The objective of this study was to investigate the effects of MP and FLX on bone morphology and biomechanical properties in adolescent rats. Four-week-old male Sprague-Dawley rats were randomly divided into the following 4 groups: Water, MP, FLX, and MP + FLX. As body weights in the MP, FLX, and MP + FLX groups were all lower than Water, the data were compared directly and after adjusting to body weight via linear regression. The direct comparison revealed that MP + FLX rats had significantly shorter (~12 %) and narrower femora and tibiae (~10 %) compared to most other groups, along with shorter (26–35 %), disorganized tibial growth plates. MicroCT analyses of the trabecular compartment of the proximal tibia identified reductions of 47 % for TV, 86 % for BV, 74 % for BV/TV, 68 % for Tb.N, 25 % in Tb.Th, and 74 % in vBMD concomitant with increases of 44 % for Tb.Sp for MP + FLX compared to Water. Similar analyses of femoral midshaft cortical bone identified reductions of 29 % for Ct.V, 30 % for Ps.V, 30 % for Ec. V, and 51 % for pMOI, as well as increases of 17 % for Ct.Th and 2 % for TMD for MP + FLX compared to Water. Biomechanically, MP + FLX femora were weaker, as indicated by a reduction in ultimate force (14 %) in MP + FLX compared to Water. The microstructural and biomechanical effects of MP + FLX were eliminated after adjustment for body weight, though the detrimental effects on growth plate morphology remained. We conclude that while the adverse microstructural and biomechanical effects of MP + FLX seen via direct comparison are predominantly attributable to reductions in body weight rather than direct effects on bone, MP and FLX, particularly in combination show detrimental effects on growth plate structure and chondrocyte morphology. These findings warrant further research into the effect of these drugs on weight gain, skeletal development and growth plate morphology, as well as consideration by physicians treating children and adolescents with ADHD. •Methylphenidate (MP) and fluoxetine (FLX) are often co-prescribed•The effects of combined MP/FLX treatment on skeletal development are unknown•Direct comparison of rats treated with MP/FLX shows impaired skeletal development•Body weight normalization eliminates most of the adverse effects of MP/FLX, indicating they are due to anorexigenic effects•MP/FLX adversely impacts growth plate morphology independent of body weight